• Profile
Close

Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

Journal of Gastroenterology and Hepatology Mar 08, 2019

Kim NH, et al. – In this study, researchers investigated the long-term efficacy and safety of CT-P13 therapy for inflammatory bowel disease (IBD). Between July 2012 and December 2017, they assessed 368 patients with IBD (227 with Crohn's disease [CD] and 141 with ulcerative colitis [UC]) who received CT-P13. At years 1, 3, and 5, cumulative retention rates were 86.1%, 68.5%, 58.7%, and 69.7%, 46.0%, and 26.7%, respectively, in patients with anti-tumor necrosis factor (TNF)-naïve CD and UC. According to outcomes, significant improvements in disease activity scores were accompanied by marked decreases in inflammatory marker levels, and no unforeseen adverse events including death or malignancy occurred during the period of study. In all, long-term CT-P13 treatment was found to be effective in inducing and maintaining improvement in disease, and was well-tolerated in this cohort of IBD patients. The investigators suggested that CT-P13 can be a promising option for IBD treatment.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay